抗凝相关脑出血重启抗凝治疗的研究进展  

Research progress on restarting anticoagulant therapy for anticoagulation related cerebral hemorrhage

作　　者：泮旭峰 吴蓉 柴海飞[1] 汪杰[1] 胡小铭[1] Pan Xufeng;Wu Rong;Chai Haifei;Wang Jie;Hu Xiaoming(Department of Neurosurgery,Taizhou Hospital of Zhejiang Province,Taizhou 317000,China;Department of Medicine,Linhai First People′s Hospital,Taizhou 317300,China)

机构地区：[1]浙江省台州医院神经外科,台州317000 [2]临海市第一人民医院内科,台州317000

出　　处：《中国医师杂志》2024年第8期1273-1276,共4页Journal of Chinese Physician

基　　金：台州市科技计划项目(20ywb15)。

摘　　要：随着人口老龄化,房颤、静脉血栓等疾病负担逐渐加重,抗凝治疗在预防上述患者缺血性卒中、肺栓塞等方面具有肯定意义。但老人跌倒事件、脑血管意外、车祸等导致颅内出血而引起的疾病状态时,抗凝治疗会起到相反的作用。在脑出血后是否重启抗凝及何时重启抗凝仍难以决断。虽然大多研究显示重启抗凝治疗可降低卒中风险且出血风险无显著升高,但多基于观察性研究,因此需要更多的高质量研究以指导临床决策。本文综述重启抗凝方面的研究进展,以期对临床应用有一定的帮助。With the aging population,the burden of diseases such as atrial fibrillation and venous thrombosis is gradually increasing.Anticoagulant therapy has a positive significance in preventing ischemic stroke,pulmonary embolism,and other related conditions in these patients.However,anticoagulant therapy can have the opposite effect on diseases caused by intracranial hemorrhage,such as falls in the elderly,cerebrovascular accidents,and car accidents.It is still difficult to determine whether and when to restart anticoagulation after cerebral hemorrhage.Although most studies have shown that restarting anticoagulant therapy can reduce stroke risk without significantly increasing bleeding risk,they are mostly based on observational studies,so more high-quality research is needed to guide clinical decision-making.This article reviews the research progress on restart anticoagulation,aiming to provide some assistance for clinical applications.

关 键 词：抗凝药 脑出血 重启抗凝 

分 类 号：R743.34[医药卫生—神经病学与精神病学]